Pfizer sues MSN Labs over Xeljanz generic

09-06-2022

Muireann Bolger

Pfizer sues MSN Labs over Xeljanz generic

Molly Woodward / Shutterstock.com

Pfizer has sued MSN Laboratories to prevent the rollout of generic copies of the blockbuster drug Xeljanz (tofacitinib citrate), used to treat patients with arthritis.


Pfizer, MSN Labs, Xeljanz, generics, US District Court for the District of Delaware, FDA, USPTO, rheumatoid arthritis

LSIPR